Trends in healthcare utilisation of patients with migraine in South Korea: a retrospective observational study using Health Insurance Review and Assessment Service National Patient Sample data from 2010 to 2018

Abstract

ObjectiveThis study used 2010–2018 Health Insurance Review and Assessment Service National Patient Sample data to analyse the distribution and healthcare utilisation of patients with migraine in South Korea.DesignRetrospective, observational study using serial cross-sectional data.ParticipantsPatients with primary diagnosis of G43, a Korean Standard Classification of Diseases-10 code for migraine, were included in the analysis. The exclusion criteria were missing code information; code for dental, health centre or psychiatry; institution type specified as nursing hospital, psychiatric hospital, dental hospital, midwifery centre or health centre; blank entries for total cost or days of care. 453 246 records of patients and 117 157 patients corresponding to those records were identified.Outcome measuresPrimary outcome measures were medical service utilisation status, treatment methods and drug use status associated with migraine.ResultsCases and patients of migraine increased from 48 846 and 19 468 (2010) to 52 729 and 20 802 (2018), respectively, increases of 7.95% and 6.85%, respectively, compared with 2010. Total cost of care increased from $921 857.88 (2010) to $1 711 219.60 (2018). The most common age range of patients was 45–54 years, with 2.69 times more female than male patients. In Western medicine hospitals, subcutaneous or intramuscular injection therapy was used frequently, while in Korean medicine hospitals, acupuncture therapy was used. Among Western medicine outpatients, more than 50% of the therapeutics prescribed for acute migraine were simple analgesics or non-steroidal anti-inflammatory drugs. The number of prescriptions for the prevention of episodic migraine increased from 13 600 cases (2010) to 20 546 cases (2018), representing the steepest increase in drug utilisation.ConclusionsTreatments frequently used in Western and Korean medicine hospitals and their frequency of use and costs were identified. The findings of this study can be used as a basis for relevant health policy decisions.

Trends and prescribing patterns of antimigraine medicines in nine major cities in China from 2018 to 2022: a retrospective prescription analysis

“…Antimigraine medicines are an essential component of optimal migraine treatment. The use of antimigraine medicines varies among countries and regions [ 6 – 8 ]. It is influenced by drug availability, drug profiles, physician and patient preferences, reimbursement and drug regulation policies, and other factors [ 2 , 9 ].…”

Associations between Chronic Kidney Disease and Migraine Incidence: Findings from a Korean Longitudinal Big Data Study

“…In Asian countries, the reported prevalence of migraine varies from 1% to 22%, which is relatively lower than the rates observed in North American countries and European countries (10-25%) [13]. Although both the prevalence of CKD and migraines in Korea seem to be lower than those in other countries, CKD and migraines are both prevalent and impactful health conditions, presenting significant challenges in both public health and clinical practice worldwide [7,9] and in Korea [8,14].…”